Current Urology Reports

, Volume 2, Issue 6, pp 495–503 | Cite as

Management of erectile dysfunction following radical prostatectomy

  • Craig D. Zippe
  • Rupesh Raina
  • Mamta Thukral
  • Milton M. Lakin
  • Eric A. Klein
  • Ashok Agarwal
Article

Abstract

Radical prostatectomy is the standard treatment for organ/ specimen-confined prostate cancer, yet erectile dysfunction in selected series is still reported as high as 90% after this procedure. Thus, most men need adjuvant treatments to be sexually active following radical prostatectomy. These include vacuum constriction devices, intracorporeal injections of vasoactive drugs, and transurethral dilators, all of which have reported response rates of 50% to 70%. Unfortunately, long-term compliance is suboptimal, with a discontinuation rate of nearly 50% at one year. These non-oral options should be offered on an individual basis to patients who have failed oral therapy since efficacy and compliance vary. Also, these options should be considered in the early postoperative period to enhance sexual activity and penile oxygenation, which may prevent corporeal fibrosis. Early penile rehabilitation with intracavernosal injections or vacuum constriction devices should be encouraged to increase chances for recovery of rigid erections. In patients with some preservation of nerve tissue, oral sildenafil may be effective in promoting an earlier return of erectile function. The potential impact of sildenafil and other new oral therapies should encourage urologists to continue to perform and perfect the nerve-sparing approach.

Keywords

Radical Prostatectomy Erectile Function Alprostadil Cavernous Nerve Intracavernosal Injection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Schrader-Bogan CL, Kjellberg JL, McPherson CP, et al.: Quality of life and treatment outcomes: prostate carcinoma patients’ perspectives after prostatectomy or radiation therapy. Cancer 1997, 79:1977–1986.CrossRefGoogle Scholar
  2. 2.
    Walsh PC, Marschke P, Ricker D, et al.: Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000, 55:58–61.PubMedCrossRefGoogle Scholar
  3. 3.
    McCullough AR: Management of erectile dysfunction following radical prostatectomy. Sex Dysfunction Med Pfizer 2000, 2(1):2–8. This excellent review discusses available treatment options for erectile dysfunction following radical prostatectomy, as well as a framework for approaching patients with erectile dysfunction following radical prostatectomy.Google Scholar
  4. 4.
    Catalona WP, Basler JW: Return of erections and urinary continence following nerve-sparing radical retropubic prostatectomy. J Urol 1993, 150:905–907.PubMedGoogle Scholar
  5. 5.
    Quinlan DM, Epstein JI, Carter BS, Walsh P: Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol 1991, 145:998–1002.PubMedGoogle Scholar
  6. 6.
    Sexton WJ, Benedict JF, Jarow JP: Comparison of long-term outcomes of penile prosthesis and intracavernosal injection therapy. J Urol 1998, 159:811–815.PubMedCrossRefGoogle Scholar
  7. 7.
    Jarow JP, Nana-Sinkam P, Sabbagh M, et al.: Outcome analysis of goal directed therapy for impotence. J Urol 1996, 155:1609–1612.PubMedCrossRefGoogle Scholar
  8. 8.
    Jarow JP, Burnett AL, Geringer AM: Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999, 162:722–725.PubMedCrossRefGoogle Scholar
  9. 9.
    Mazur DJ, Merz JF: Older patients’ willingness to trade off urologic adverse outcomes for a better chance at five-year survival in the clinical setting of prostate cancer. J Am Geriatr Soc 1995, 43:979–984.PubMedGoogle Scholar
  10. 10.
    Talcott JA, Rieker P, Propert KJ, et al.: Patient reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 1997, 89:1117–1123.PubMedCrossRefGoogle Scholar
  11. 11.
    Valdivia Navarro P, Gonzalvo A, Blas Marin M, et al.: Quality of life after radical prostatectomy. Actas Urol Esp 1997, 21:903–908.Google Scholar
  12. 12.
    Zippe CD, Thukral M, Agarwal A, et al.: Erectile dysfunction following radical prostatectomy in a pre-operative sexually active population. Poster presentation at the 95th Annual Meeting of the American Urological Association, Atlanta, 2000.Google Scholar
  13. 13.
    Dutta TC, Eid JF: Vacuum constriction devices for erectile dysfunction: a long-term, prospective study of patients with mild, moderate, and severe dysfunction. Urology 1999, 54(5):891–893.PubMedCrossRefGoogle Scholar
  14. 14.
    Cookson MS, Nadig PW: Long term results with vacuum constriction device. J Urol 1993, 149:290–294.PubMedGoogle Scholar
  15. 15.
    Turner LA, Althof SE, Levine SB, et al.: Twelve-month compari-son of two treatments for erectile dysfunction: self-injection versus external vacuum devices. Urology 1992, 39(2):139–144.PubMedCrossRefGoogle Scholar
  16. 16.
    Soderdahl DW, Thrasher JB, Hansberry KL: Intracavernosal drug-induced erection therapy versus external vacuum devices in the treatment of erectile dysfunction. Br J Urol 1997, 79:952–957. This interesting study compares two competing treatment options for erectile dysfunction.PubMedGoogle Scholar
  17. 17.
    Gould JE, Switters DM, Broberick GA, deVereWhite RW: External vacuum devices: a clinical comparison with pharmacologic erections. Wor l d J Ur ol 1992, 10:68–70.Google Scholar
  18. 18.
    Blackard CE, Borken WD, Lima JS, et al.: Use of vacuum tumescence device for impotence secondary to venous leakage. Urology 1996, 41:225–227.CrossRefGoogle Scholar
  19. 19.
    Sidi AA, Becher EF, Zhang G, Lewis JH: Patient acceptance of and satisfaction with an external negative pressure device for impotence. J Urol 1990, 144:1154–1156.PubMedGoogle Scholar
  20. 20.
    Fraiman MC, Lepor H, Telegrafi S, et al.: Does early treatment of erectile dysfunction after nerve sparing radical prostatec-tomy lead to better long term return of natural function? [abstract]. In Proceedings of the Society for the Study of Impotence Meeting, 2000. Cleveland, OH: Society for the Study of Impo-tence; 2000.Google Scholar
  21. 21.
    Zippe CD, Raina R, Agarwal A, et al.: Recovery of spontaneous erectile function after radical prostatectomy with or without early use of VCD. Paper presented at the North Central Section Meeting of the American Urological Association, Cancun, Mexico, 2001.Google Scholar
  22. 22.
    Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al.: Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997, 336:1–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Costabile RA, Govier FE, Ferrigni RG, et al.: Safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1997, 157(4):1424.Google Scholar
  24. 24.
    Paolone DR, Lankin MM, Ingleright BJ, et al.: Intraurethral alprostadil therapy at The Cleveland Clinic Foundation. Abstract submitted to North Central Section American Urological Association Meeting, Amelia Island, FL, 1998.Google Scholar
  25. 25.
    Thukral M, Lakin MM, Agarwal A, et al.: Effectiveness of MUSE for erectile dysfunction after radical prostatectomy. Abstract submitted to the 74th North Central Section American Urological Association Meeting, Scottsdale, AZ, 2000.Google Scholar
  26. 26.
    Porst H: Transurethral alprostadil with MUSE versus intra-cavernous alprostadil: a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997, 9:187–192.PubMedCrossRefGoogle Scholar
  27. 27.
    Nehra A, Hakin LS, Barrett DM: Combination of sildenafil and intraurethral prostaglandin E1 salvaged a selected popula-tion of men with ED. Abstract submitted to the 95th Annual Meet-ing of the American Urological Association, Atlanta, 2000.Google Scholar
  28. 28.
    Brindley GS: Pilot experiments on the action of drugs injected into the human corpus cavernosum penis. Br J Pharmacol 1986, 87:405–500.Google Scholar
  29. 29.
    Stakl W, Hasun R, Marberger N: Prostaglandin E-1 in the treatment of erectile dysfunction. Wor l d J Ur ol 1990, 8:84–86.CrossRefGoogle Scholar
  30. 30.
    Khan MA, Thompson CS, Sullivan ME, et al.: The role of pros-taglandins in the aetiology and treatment of erectile dysfunc-tion. Prostaglandins Leukot Essent Fatty Acids 1999, 60:169–174.PubMedCrossRefGoogle Scholar
  31. 31.
    Mc Mahon R: A pilot study for the role of intracavernosal injection of vasoactive intestinal polypeptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction. Int J Impot Res 1996, 8:233–236.Google Scholar
  32. 32.
    Dennis RL, McDougal WS: Pharmacological treatment of erectile dysfunction after radical prostatectomy. J Urol 1988, 139:775–776.PubMedGoogle Scholar
  33. 33.
    Rodriguez Vela L, Gonzalvo Ibarra A, Bono Arino A, et al.: Erec-tile dysfunction after radical prostatectomy. Etiopathology and treatment [in Spanish]. Actas Urol Esp 1997, 21:909–921.Google Scholar
  34. 34.
    Lakin MM, Chen RN, Llorens SA, et al.: Prostaglandin E1 injection therapy for post-prostatectomy impotence: an outcome analysis. J Urol 1996, 155:639.CrossRefGoogle Scholar
  35. 35.
    Evans C: Complications of intracavernosal therapy for impotence. In Textbook of Erectile Dysfunction. Edited by Carson C, Kirby R, Goldstein I. Oxford, UK: Isis Medical Media; 1999:365–370.Google Scholar
  36. 36.
    Mulhall JP, Jahoda A, Cairney M, et al.: The causes of patient dropout from penile self-injection therapy for impotence. J Urol 1999, 162:1291–1294.PubMedCrossRefGoogle Scholar
  37. 37.
    Purvis K, Egdetveit I, Christiansen E: Intracavernosal therapy for erectile failure—Impact of treatment and reasons for dropout and dissatisfaction. Int J Impot Res 1999, 11:287–299.PubMedCrossRefGoogle Scholar
  38. 38.
    Thukral M, Lakin MM, Agarwal A, et al.: Analysis of intracorpo-real (IC) penile injection treatment based on the IIEF questionnaire in patients with erectile dysfunction following radical prostatectomy. Poster #4 presented at the 74th Annual North Central Section American Urological Association Meeting, Scottsdale, AZ, 2000.Google Scholar
  39. 39.
    Moreland RB, Abdulmaged T, McMillin MA, et al.: PGE1 suppresses the induction of collagen synthesis by transforming growth factor beta 1 in human corpus cavernosum smooth muscle. J Urol 1998, 153:811–815.Google Scholar
  40. 40.
    Fraiman MC, Lepor H, McCullough AR: Changes in penile morphometrics in men with erectile dysfunction after nerve-sparing radical prostatectomy. Mol Urol 1999, 3:109–115.Google Scholar
  41. 41.
    Montorsi F, Guazzoni G, Strambi LF, et al.: Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavern-ous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997, 158:1408–1410. This article introduced an exciting new approach to erectile dysfunc-tion therapy for prophylactic pharmocotherapy to prevent erectile dysfunction or restoring early return of erectile function following radical prostatectomy.PubMedCrossRefGoogle Scholar
  42. 42.
    Willke RJ, Glick HA, McCarron TJ, et al.: Quality of life effects of alprostadil therapy for erectile dysfunction. J Urol 1997, 157:2124–2127.PubMedCrossRefGoogle Scholar
  43. 43.
    Goldstein I, Lue TF, Padma-Nathan H, et al.: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group N Engl J Med 1998, 338:1397–1404.Google Scholar
  44. 44.
    Zagaja GP, Mhoon DA, Aikens JE, Brendler CB: Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology 2000, 56(4):631–634. This study shows the result of sildenafil citrate in men with erectile dysfunction following radical prostatitis. An excellent discussion of the use, effectiveness, and side effects of the first approved PDE5 agent.PubMedCrossRefGoogle Scholar
  45. 45.
    Feng MI, Huang S, Kaptein J, et al.: Effect of sildenafil citrate on post-radical prostatectomy erectile dysfunction. J Urol 2000, 164:1935–1938.PubMedCrossRefGoogle Scholar
  46. 46.
    Zippe CD, Thurkal M, Agarwal A, et al.: The erectile dysfunc-tion following radical prostatectomy. Indian J Urol 2000.Google Scholar
  47. 47.
    Zippe CD, Kedia S, Kedia AW, Pasqualotto F: Sildenafil citrate (Viagra) after radical retropubic prostatectomy: pro. Urology 1999, 54:583–586.PubMedCrossRefGoogle Scholar
  48. 48.
    Zippe CD, Jhaveri FM, Klein EA, et al.: Role of Viagra after radical prostatectomy. Urology 2000, 55(2):241–245.PubMedCrossRefGoogle Scholar
  49. 49.
    Hong EK, Lepor H, McCullough AR: Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve sparing radical retropubic prostatectomy. Int J Impot Res 1999, 11:15–22.CrossRefGoogle Scholar
  50. 50.
    Klotz L, Herschorn S: Early experience with intraoperative cavernous nerve stimulation with penile tumescence monitoring to improve nerve sparing during radical prostatectomy. Urology 1998, 52(4):537–542.PubMedCrossRefGoogle Scholar
  51. 51.
    Rogers RS, Lin C-S, Lau A, et al.: Expression of three isoform of cGMP binding cGMP specific phosphodiestrase (PDE 5) in penile cavernosum. Abstract No. 862. AUA 95th Annual Meeting, Atlanta, 2000.Google Scholar
  52. 52.
    Giuliano F, Porst H, Padmanathan H, et al.: Daily and on-demand IC351 treatment of erectile dysfunction. Abstract No. 894. AUA 95th Annual Meeting, Atlanta, 2000.Google Scholar
  53. 53.
    Sachse R, Rohde G, Stark S, Klotz T: Safety, tolerability and pharmacokinetics of bay 38-9456 in patients with erectile dysfunction. Abstract No.904. AUA 95th Annual Meeting, Atlanta, 2000.Google Scholar
  54. 54.
    Sunderland S: Nerve grafting and related methods of nerve repair. In Nerve Injuries and Their Repair: A Critical Appraisal. Edinburgh: Churchill Livingstone; 1991:467–497.Google Scholar
  55. 55.
    Kim ED, Nath R, Kadmon D, et al.: Bilateral nerve graft during radical retropubic prostatectomy: 1 year follow-up. J Urol 2001, 165:1950–1956.PubMedCrossRefGoogle Scholar
  56. 56.
    Bakircioglu ME, Lin CS, Wefer J, et al.: The effect of adenoassociated virus mediated brain derived neurotrophic factor in an animal model for neurogenic impotence. J Urol 2000, 163:198.Google Scholar
  57. 57.
    Lee MC, El-Sakka A, Bakircioglu E: The effect of vascular endothelial growth factor on a rat model of arterial impotence. J Urol 2000, 163:198.Google Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Craig D. Zippe
    • 1
  • Rupesh Raina
    • 1
  • Mamta Thukral
    • 1
  • Milton M. Lakin
    • 1
  • Eric A. Klein
    • 1
  • Ashok Agarwal
    • 1
  1. 1.The Cleveland Clinic FoundationAndrology-Urology Research Laboratory, Urological InstituteClevelandUSA

Personalised recommendations